Eli Lilly Files Six Lawsuits, Reports 200+ Illegal Retatrutide Sellers to Authorities
LLY sits 94% above its 52-week low of $629.398 on light trading volume (0.2× avg).
Summary
Eli Lilly is escalating its fight against black-market retatrutide, filing six new lawsuits against U.S. businesses and referring over 200 offenders to the FDA, DOJ, and state attorneys general. The company is also pressuring payment processors, e-commerce platforms, and shipping carriers to cut ties with illegal sellers, having flagged over 14,000 fraudulent listings across 100+ countries. This crackdown protects the commercial potential of retatrutide, a key pipeline asset in the booming GLP-1 obesity market, and signals Lilly's aggressive defense of its intellectual property and patient safety. The action follows strong Phase 3 data and FDA approval of oral Foundayo, reinforcing Lilly's dominance in the weight-loss space. Watch for any regulatory or platform responses that could further curb illicit supply.
At the time of this announcement, LLY was trading at $1,220.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $629.40 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.